Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Among authors: combe b. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study.
Buch MH, Aletaha D, Combe BG, Tanaka Y, Caporali R, Schulze-Koops H, Takeuchi T, Gottenberg JE, Blanco R, Verschueren P, Zubrzycka-Sienkiewicz A, De Leonardis F, Ekoka Omoruyi EV, Rajendran V, Emery P. Buch MH, et al. Among authors: combe bg. RMD Open. 2024 Oct 24;10(4):e004476. doi: 10.1136/rmdopen-2024-004476. RMD Open. 2024. PMID: 39455065 Free PMC article. Clinical Trial.
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter KM, Camp HS, Rubbert-Roth A. Fleischmann R, et al. Among authors: combe b. RMD Open. 2024 Jul 25;10(3):e003918. doi: 10.1136/rmdopen-2023-003918. RMD Open. 2024. PMID: 39059811 Free PMC article. Clinical Trial.
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024.
de Prost N, Audureau E, Guillon A, Handala L, Préau S, Guigon A, Uhel F, Le Hingrat Q, Delamaire F, Grolhier C, Tamion F, Moisan A, Darreau C, Thomin J, Contou D, Henry A, Daix T, Hantz S, Saccheri C, Giordanengo V, Pham T, Chaghouri A, Bay P, Pawlotsky JM, Fourati S; SEVARVIR investigators. de Prost N, et al. Ann Intensive Care. 2024 Jun 28;14(1):101. doi: 10.1186/s13613-024-01319-w. Ann Intensive Care. 2024. PMID: 38940865 Free PMC article.
556 results